Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)

Model scores of the 29,894 trials active now.

Model score 29% for any early termination, 9% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2024-07-01. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: patientcancerradiationto determinesquamous cell
  Phrases that lowered it: armefficacy andcopdantiretroviralthe efficacy
• Sponsor's past termination rate: 16.6% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: parallel (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 128 (lowers risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor's past trials: 349 (lowers risk) · Sponsor's track record
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 11136 (lowers risk) · Drug's FDA history
• Drug's FAERS reports with a death: 20.8% (lowers risk) · Drug's FDA history
• Drug's FAERS reports before start: 69244 (lowers risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Drugs with FDA adverse-event history: 4 (lowers risk) · Drug's FDA history
• Collaborators: 1 (raises risk) · Design
• Number of arms: 3 (lowers risk) · Design
• Blinding: none (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Induction Chemotherapy With ACF Followed by Chemoradiation Therapy for Adv. Head & Neck Cancer NCT01566435 · started 2012 · scored riskier than 99% of active trials completed
• Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma NCT02277184 · started 2015 · scored riskier than 64% of active trials terminated
• A Study for Participants With Recurrent or Metastatic Squamous Cell Head and Neck Cancer NCT01087970 · started 2010 · scored riskier than 52% of active trials completed
• Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX) NCT04282109 · started 2020 · scored riskier than 87% of active trials completed
• Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck NCT01412229 · started 2012 · scored riskier than 99% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.